Skip to content Skip to footer
Subscribe Now
NEWS

CSPC Group and AstraZeneca Partner to Develop siRNA Drugs in ~$1.77B Deal

Shots: CSPC & AstraZeneca have entered into a strategic collaboration, option & license agreement to leverage CSPC’s siRNA discovery & extrahepatic targeted delivery platforms to develop novel small nucleic acid therapeutics CSPC & AstraZeneca will jointly discover & develop preclinical candidates for two renal disease targets, with AstraZeneca holding options for global/ex-China rights to each…
July 3, 2026

Read more

NEWS

AlzeCure Partners with QuantumCell for NeuroRestore ACD856 in a Deal Worth up to $2.2B

Shots: AlzeCure Pharma has entered into an out-licensing & collaboration agreement with QuantumCell for global rights to AlzeCure’s Alzheimer’s platform NeuroRestore, incl. ACD856 AlzeCure will receive $12M upfront, incl. a $5M investment, & is eligible for development & commercial milestones exceeding $2.2B (excl. royalties), plus tiered single to low double-digit royalties NeuroRestore ACD856 is a…
July 3, 2026

Read more

NEWS

Insilico Medicine Collaborates with Takeda to Advance AI Drug Discovery

Shots: Insilico Medicine has entered into a strategic collaboration agreement with Takeda to advance clinically differentiated drug candidates across Takeda's therapeutic areas, using Insilico’s Pharma.AI platform Insilico will lead AI-driven discovery, while Takeda will advance selected candidates through clinical development & hold exclusive worldwide rights to develop, manufacture, & commercialize resulting therapeutics As per the…
July 2, 2026

Read more

NEWS

Boulevard Bio Inks ~$1.62B Licensing Deal with METiS TechBio for MTS-128

Shots: METiS TechBio has granted Boulevard worldwide development, manufacturing, and commercialization rights to MTS-128, a trispecific T-cell engager (TCE) program As per the deal, METiS TechBio will receive a $20M upfront payment & ~$1.6B in development, regulatory, & commercial milestone payments, in addition to tiered royalties on product sales MTS-128 is a trispecific T-cell engager…
June 30, 2026

Read more

NEWS

LENZ Therapeutics Partners with Arrotex Pharmaceuticals to Commercialize Vizz in Australia and New Zealand

Shots: LENZ has entered into an exclusive license & commercialization agreement with Arrotex to register & commercialize Vizz (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in Australia & New Zealand As per the deal, Arrotex will obtain exclusive commercialization rights for Vizz for the treatment of presbyopia in Australia & New Zealand. In return,…
June 26, 2026

Read more

NEWS

CStone Pharmaceuticals Partners with Arrotex to Commercialize Sugemalimab across Australia and New Zealand

Shots: CStone Pharmaceuticals has entered into an exclusive commercialization agreement with Arrotex for the commercialization of sugemalimab in Australia & New Zealand As per the deal, Arrotex will be responsible for regulatory submissions & obtain exclusive commercialization rights for sugemalimab in Australia & New Zealand across all approved & future indications In return, CStone will…
June 26, 2026

Read more

NEWS

Antares Therapeutics Inks ~$1.9B Deal with Novartis for Undruggable Oncology Targets

Shots: Antares Therapeutics has entered into a strategic collaboration with Novartis to discover, develop & commercialize small molecule therapies against undruggable oncology targets Antares will lead research & apply its discovery engine to a select number of historically undruggable targets until option exercise, while continuing to advance its wholly owned & partnered precision medicine pipeline…
June 25, 2026

Read more

NEWS

Combotope Therapeutics and Boehringer Ingelheim Collaborate on Next-Generation Cancer Antibody Therapies

Shots: BI has entered into a strategic research collaboration with Combotope to leverage its SMART-Phage platform to produce highly tumor-selective antibodies for next-generation cancer therapies Combotope will discover tumor-selective, high-affinity antibodies against multiple BI oncology targets, while BI will hold global development & commercialization rights, and lead further R&D, manufacturing, & commercialization activities As per…
June 24, 2026

Read more

Load more